Tet methylcytosine dioxygenase 2 (TET2; also known as ten-eleven translocation 2) is a gene that codes for a protein involved in epigenetic
regulation of myelopoeisis (Gene 2014; Solary et al.
2014). TET2 is a tumor suppressor, and so in cancer, loss of TET2 function, which
can occur via TET2 mutation, TET2 deletion, or IDH1 or IDH2 mutation, can cause myeloid or
lymphoid transformations (Solary et al. 2014). Mutations in TET2 have
been found in MDS, AML, ALL, and other hematologic malignancies.
Suggested Citation: Strickland, S., A. Kim. 2015. TET2. My Cancer
(Updated December 4).
Last Updated: December 4, 2015
TET2 in Myelodysplastic Syndromes
TET2 mutations occur in 18.7% of MDS (COSMIC). TET2 mutations are observed in all types of MDS, and they
tend to co-occur with SRFS2 in chronic myelomonocytic leukemia (CMML), a subtype of MDS (Cazzola, Della
Porta, and Malcovati 2013). TET2 mutations are believed to cause loss of function
(Solary et al.
2014). TET2 is a tumor suppressor gene, and so loss-of-function mutations support
the abnormal hematopoiesis observed in MDS (Solary et al.
2014). These mutations are found spread throughout the gene.
TET2 mutations are a neutral or favorable
prognostic biomarker (Bejar
et al. 2011; Kosminder
et al. 2009; NCCN 2014). However, Bejar et al. (2014)
observed that TET2 mutations predict shorter overall survival following hematopoietic stem
Suggested Citation: Strickland, S., A. Kim. 2014. TET2 in Myelodysplastic
Syndromes. My Cancer Genome https://www.padiracinnovation.org/content/disease/myelodysplastic-syndromes/tet2/
(Updated September 23).
Last Updated: September 23, 2014
My Cancer Genome has released its new and improved cancer clinical trials search tool on our
beta website. Please visit beta.padiracinnovation.org
to check it out!